Prothena Corporation plc (NASDAQ: PRTA) announced results from its Phase 1 ASCENT clinical program testing PRX012, an anti-amyloid beta antibody ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE